Lilly Q4 revenue beats estimates led by Mounjaro and Zepbound

Overview

• Pharmaceutical firm's Q4 revenue rose 43% yr/yr, beats analyst expectations

• Adjusted EPS for Q4 beat analyst expectations

• Company issued 2026 guidance with revenue projected between $80 bln and $83 bln

Outlook

• Lilly forecasts 2026 revenue between $80 bln and $83 bln

• Company expects 2026 non-GAAP EPS between $33.50 and $35.00

• Lilly anticipates 2026 tax rate between 18% and 19%

Result Drivers

• VOLUME GROWTH - Revenue increase driven by 46% rise in volume, led by Mounjaro and Zepbound

• REGULATORY PROGRESS - FDA approvals and submissions for new indications and products contributed to results

• GOVERNMENT AGREEMENT - Agreement with U.S. government to expand access to obesity medicines

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 24 "strong buy" or "buy", 9 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy"

• Wall Street's median 12-month price target for Eli Lilly and Co is $1,163.00, about 15.9% above its February 3 closing price of $1,003.46

• The stock recently traded at 30 times the next 12-month earnings vs. a P/E of 29 three months ago

Press Release: ID:nPn4XszNHa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.